-
Raymond James Downgrades Third Harmonic Bio (THRD) to Market Perform
-
Third Harmonic Bio (THRD) Announces Phase 1 Clinical Results for THB335, Provides Corporate Strategic Update
-
Third Harmonic Bio (THRD) PT Lowered to $7 at Jefferies
-
Stifel on Celldex (CLDX) and Third Harmonic Bio (THRD): 'we continue to like the prospects of CLDX and THRD as both first-in-class and an oral pure-play'
-
Stifel Reiterates Buy Rating on Third Harmonic Bio (THRD)
-
Morgan Stanley Upgrades Third Harmonic Bio (THRD) to Overweight
-
Stifel Starts Third Harmonic Bio (THRD) at Buy

